Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer will acquire AstraZeneca business

by Michael McCoy
August 29, 2016 | A version of this story appeared in Volume 94, Issue 34

Pfizer has agreed to acquire AstraZeneca’s late-stage small-molecule antibiotics business, primarily outside the U.S., for $725 million and up to $850 million in future payments. The business includes Zavicefta, recently approved in the European Union; the marketed products Merrem and Zinforo; and two products in clinical development. AstraZeneca spun off its antibiotics R&D efforts as Entasis Therapeutics last year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.